HER-2 inhibitors: clinical results.
Crinò
Lucio
L
Division of Medical Oncology, Bellaria Hospital, Bologna, Italy.
Franceschi
Enrico
E
Scopece
Luciano
L
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000502:physiology*; D006801:Humans; D008024:Ligands; D008175:Lung Neoplasms / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013629:Tamoxifen / Q000494:pharmacology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D008024:Ligands; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D000068878:Trastuzumab